At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
IRL201104 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Double-blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of IRL201104 in Adult Participants With Active Eosinophilic Esophagitis (EoE)
In Brief
A Phase 2 clinical trial evaluating IRL201104 and Placebo for Eosinophilic Esophagitis. Completed, enrolled 36 participants across 23 sites.
Detailed Summary
The purpose of this study is to asses the efficacy, safety and tolerability of repeat doses of IRL201104 in Adult Participants with Active Eosinophilic Esophagitis (EoE)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Esophagitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartOct 2021
Primary CompletionOct 2022
TodayJul 2026
First PostedOct 20, 2021
Enrollment StartOct 29, 2021
Primary CompletionOct 24, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.7 years ago
Interventions
IRL201104drug
lyophilised powder for reconstitution for IV dosing
Placebodrug
Matching placebo for IRL201104